Quality standard
Quality statement 5: Hormone‑relapsed metastatic prostate cancer
Quality statement 5: Hormone‑relapsed metastatic prostate cancer
Quality statement
People with hormone‑relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer multidisciplinary team (MDT).
Rationale
Discussion by the urological cancer MDT is a means of ensuring that an opinion from an oncologist and/or palliative care specialist is obtained. Having a variety of opinions from experts who are aware of all current treatment options means that there is a better chance to identify the best options for the person. Those options can then be discussed with the person.
Quality measures
The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples of how the statement can be measured, and can be adapted and used flexibly.
Structure
Evidence of local arrangements to ensure that people with hormone‑relapsed metastatic disease have their treatment options discussed by the urological cancer MDT.
Data source: Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, from service specifications or local protocols.
Process
Proportion of people with hormone‑relapsed metastatic disease who have their treatment options discussed by the urological cancer MDT.
Numerator – the number in the denominator who have their treatment options discussed by the urological cancer MDT.
Denominator – the number of people with hormone‑relapsed metastatic prostate cancer.
Data source: Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, from patient records.
What the quality statement means for different audiences
Service providers (such as hospitals, specialist urological cancer MDTs and specialist prostate cancer services) ensure that systems are in place for people with hormone‑relapsed metastatic prostate cancer to have their treatment options discussed by the urological cancer MDT.
Healthcare professionals ensure that people with hormone‑relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer MDT.
Commissioners (such as integrated care systems, clinical commissioning groups and NHS England) monitor whether providers have systems in place to ensure that people with hormone‑relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer MDT.
People with cancer that has spread outside the prostate and whose drug treatment (to block the production of hormones that help cancer cells to grow) has stopped working have their treatment options discussed by a specialist team of healthcare professionals with different kinds of expertise in prostate cancer. This is to make sure that all the different treatment options are discussed and all suitable treatments are offered.
Source guidance
Prostate cancer: diagnosis and management. NICE guideline NG131 (2021), recommendation 1.5.11
Definitions of terms used in this quality statement
Hormone‑relapsed prostate cancer
Prostate cancer after failure of primary androgen deprivation therapy. [NICE's guideline on prostate cancer, terms used in this guideline]
Urological cancer MDT
A team that includes specialists in urology, oncology, pathology, radiology, palliative care, diet and nursing. [Adapted from NICE's 2014 full guideline on prostate cancer and the British Uro-Oncology Group and British Association of Urological Surgeons MDT (multi-disciplinary team) guidance for managing prostate cancer]